Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of ...

Lineage Cell Therapeutics, Inc.’s LCTX share price has dipped by 6.64%, which has investors questioning if this is right time to buy.

The inner ear contains distinct sensory organs, produced sequentially by segregation from a large sensory-competent domain in the developing otic vesicle. To understand the mechanistic basis of this ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

A recent study marks the first reported instance of generative AI designing synthetic molecules that can successfully control gene expression in healthy mammalian cells. As a proof-of-concept, the ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal ...

Building a chromosome from scratch may sound like science fiction, but scientists have actually done it-and made it work. In ...

Ranieri Cancedda's research in bioengineering and biotechnology has significantly advanced the understanding of cellular and molecular mechanisms over the ...

This study exploring the role of TRPV1 signaling in recruiting macrophages and promoting angiogenesis during tympanic membrane wound healing presents useful findings. However, the strength of evidence ...